Paige, founded in 2017 by Thomas Fuchs and colleagues from Memorial Sloan Kettering Cancer Center, builds AI models for digital pathology, helping pathologists analyze tissue slides for cancer diagnosis, subtyping, and molecular biomarker discovery with its Paige Alba AI co-pilot for pathology workflows.
Tempus, the genomics and precision-medicine data company, acquired Paige in August 2025, and Paige continues operating and developing its pathology-specific AI under its own brand and product line within Tempus's broader precision-medicine business rather than being folded into an undifferentiated product.
Pricing runs enterprise, with dedicated support and custom deployment scoped to a hospital or lab's pathology volume. For a pathology department that wants AI assistance analyzing tissue slides for cancer diagnosis, Paige's Memorial-Sloan-Kettering-rooted, now Tempus-backed platform addresses that directly.
